Quick Tips

Why is it important for APs to incorporate palliative care into the management of their patients, and what are some of the barriers to doing so?

Charles von Gunten, MD, PhD, on integrating palliative care into practice.

Learn more on this topic: KEYNOTE ADDRESS: Integrating Palliative Care Into the Cancer Care Setting: The Role of the Advanced Practitioner

What are the risk factors and prevention strategies for throat cancer?

Julie E. Bauman, MD, MPH, on head and neck cancer: multimodality treatments.

What are the best ways to manage the adverse events of EGFR and ALK inhibitors?

Marianne Davies, DNP, ACNP, AOCNP, and Beth Eaby-Sandy, MSN, CRNP, on managing side effects for patients with thoracic tumors receiving multimodality therapy.

Learn more on this topic: Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology

What are the best ways to minimize the adverse events of checkpoint inhibitors?

Beth Eaby-Sandy, MSN, CRNP, and Marianne Davies, DNP, ACNP, AOCNP, on managing side effects for patients with thoracic tumors receiving multimodality therapy.

Learn more on this topic: Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology

What are the best ways to manage the toxicities of current and emerging treatments for advanced prostate cancer?

Morgane Diven, PharmD, BCOP, on therapeutic advances in prostate cancer.

Learn more on this topic: Therapeutic Advances in Prostate Cancer

What do the data say about emerging agents for the treatment of nonmetastatic castration-resistant prostate cancer in men who have rapidly rising PSA levels?

Robert Dreicer, MD, on therapeutic advances in prostate cancer.

Learn more on this topic: Therapeutic Advances in Prostate Cancer

How do I distinguish the differential diagnoses of plasma cell dyscrasias?

Beth Faiman, PhD, APRN-BC, AOCN, and Rachid Baz, MD, on advances in the management of plasma cell dyscrasias.

Learn more on this topic: Advancing the Management of Plasma Cell Dyscrasias

What are the appropriate management strategies for patients with MGUS and smoldering multiple myeloma?

Beth Faiman, PhD, APRN-BC, AOCN, and Rachid Baz, MD, on advances in the management of plasma cell dyscrasias.

Learn more on this topic: Advancing the Management of Plasma Cell Dyscrasias

What is the best way to manage symptoms during treatment intended to cure head and neck cancer?

Abby Fuoto, RN, ANP, on head and neck cancer: multimodality treatments.

What are the best ways to monitor minimal residual disease in myeloid malignancies?

Melinda Tran, PharmD, BCOP, and Kelda Gardner, PA-C, MHS, on new directions in myeloid malignancies.

Learn more on this topic: New Directions in Myeloid Malignancies

How can minimal residual disease be used to predict response to treatment for myeloid malignancies?

Melinda Tran, PharmD, BCOP, and Kelda Gardner, PA-C, MHS, on new directions in myeloid malignancies.

Learn more on this topic: New Directions in Myeloid Malignancies

What are the rationales for lumpectomy, mastectomy, and mastectomy with reconstruction?

Sherry Goldman, NP, CBCN, on breast cancer: the surgical implications.

What are the benefits and disadvantages of nipple-sparing surgery?

Sherry Goldman, NP, CBCN, on breast cancer: the surgical implications.

What are the best ways to prevent and reduce adverse events of immune checkpoint inhibitors in patients with classical Hodgkin lymphoma?

Amy Goodrich, CRNP, on managing treatment-related events in classical Hodgkin lymphoma.

Learn more on this topic: Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma

What is the best way to counsel patients with classical Hodgkin lymphoma on the early detection and prevention of adverse events?

Amy Goodrich, CRNP, on managing treatment-related events in classical Hodgkin lymphoma.

Learn more on this topic: Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma

What are the indications of agents approved in 2017–2018 for patients with solid tumors?

Patrick J. Kiel, PharmD, BCPS, BCOP, on new drug updates in solid tumors.

Learn more on this topic: New Drug Updates in Solid Tumors

What are the signs and symptoms of serious adverse events from the newly approved oncology drugs for solid tumors?

Patrick J. Kiel, PharmD, BCPS, BCOP, on new drug updates in solid tumors.

Learn more on this topic: New Drug Updates in Solid Tumors

What are the best ways to manage the side effects of targeted treatments and immunotherapies for advanced and metastatic melanoma?

Lisa Kottschade, NP, and Svetomir N. Markovic, MD, PhD, on evolving therapies in managing melanoma.

Learn more on this topic: Evolving Therapies in the Clinical Management of Melanoma

How do I evaluate the data on immunotherapies used to treat advanced or metastatic melanoma?

Lisa Kottschade, NP, and Svetomir N. Markovic, MD, PhD, on evolving therapies in managing melanoma. 

Learn more on this topic: Evolving Therapies in the Clinical Management of Melanoma

What are the latest tests for molecular abnormalities in hematologic cancers?

Sandra E. Kurtin, PhDc, ANP-C, AOCN, and Jennifer Knight, MD, on differential diagnosis and testing in hematologic malignancies.

Learn more on this topic: Differential Diagnosis and Testing for Hematologic Malignancies

What do I need to know about preventing and reducing the side effects of agents used in patients with classical Hodgkin lymphoma?

Jose D. Sandoval-Sus, MD, on managing treatment-related events in classical Hodgkin lymphoma. 

Learn more on this topic: Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma

What are the recent findings comparing the safety and efficacy of standard blood-thinning treatment with the newer direct oral anticoagulants?

Rowena Schwartz, PharmD, BCOP, on the role of direct oral anticoagulants in venous thrombosis.

Learn more on this topic: Preventing and Treating Venous Thrombosis in Oncology

How do I evaluate the risks and benefits of treatment with direct oral anticoagulants?

Rowena Schwartz, PharmD, BCOP, on venous thrombosis: treatment risks and benefits.

Learn more on this topic: Preventing and Treating Venous Thrombosis in Oncology

What are the emerging data supporting combination therapies in chronic lymphocytic leukemia?

Lisa Nodzon, PhD, ARNP, AOCNP, and Philip A. Thompson, MB, on emerging data in indolent lymphomas.

Learn more on this topic: Sequencing Therapies in Indolent Lymphomas (FL and CLL)

How do I monitor patients with chronic lymphocytic leukemia/small lymphocytic lymphoma for 17p deletion at diagnosis and throughout the course of the disease?

Philip A. Thompson, MB, and Lisa Nodzon, PhD, ARNP, AOCNP, on sequencing therapies in indolent lymphomas.

Learn more on this topic: Sequencing Therapies in Indolent Lymphomas (FL and CLL)

What is the appropriate use of new agents for mantle cell lymphoma?

Learn more on this topic: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating mantle cell lymphoma.

What is the potential of emerging therapies?

Learn more on this topic: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating aggressive B-cell lymphomas.

What are the current treatments for relapsed/refractory DLBCL?

Learn more on this topic: Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

Barbara Rogers, CRNP, MN, AOCN, ANP-BC, on treating aggressive B-cell lymphomas.

How do I manage minimal residual disease?

Learn more on this topic: Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, on treating acute myeloid leukemia.

What are the best ways to manage the side effects of AML therapies?

Learn more on this topic: Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN, on treating acute myeloid leukemia.

What are the germline mutations in patients predisposed to MPN/MDS?

Learn more on this topic: Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What should I know about the JAK-STAT biochemical signaling pathway?

Learn more on this topic: Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What are the latest WHO disease definitions for diagnosing myeloproliferative neoplasms?

Learn more on this topic: Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Sandra E. Kurtin, PhDc, ANP-C, AOCN, on treating Ph- myeloproliferative neoplasms.

What are the mechanisms of action and use of PD-1 inhibitors in the treatment of classical Hodgkin lymphoma?

Learn more on this topic: Emerging Therapies for Hodgkin Lymphoma

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating Hodgkin lymphoma.

What are the emerging therapies for relapsed or refractory classical Hodgkin lymphoma?

Learn more on this topic: Emerging Therapies for Hodgkin Lymphoma

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating hodgkin lymphoma.

What are the best care strategies for patients with relapsed/refractory multiple myeloma who need maintenance therapy?

Learn more on this topic: Emerging Therapies for Multiple Myeloma

Patrick J. Kiel, PharmD, BCPS, BCOP: on treating multiple myeloma.

What are the prognostic factors and risk-adaptive strategies for making treatment decisions in follicular lymphoma?

Learn more on this topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

What are the latest data on newly approved agents for primary, relapsed, and refractory follicular lymphoma?

Learn more on this topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

What are the best strategies for managing the side effects of medications for follicular lymphoma?

Learn more on this topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating follicular lymphoma.

How do I incorporate emerging therapies into treatment plans for patients with CLL?

Learn more on this topic: Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Amy Goodrich, MSN, CRNP, on treating chronic lymphocytic leukemia.

How useful is biomarker testing in choosing patients for immunotherapy?

Learn more on this topic: Immunotherapy: Treatment-Related Issues

Whitney Lewis, PharmD, BCOP, on biomarker testing.

What is the rationale for sequencing and combining immunotherapy with chemotherapy?

Learn more on this topic: Immunotherapy: Treatment-Related Issues

Whitney Lewis, PharmD, BCOP, on using immunotherapy vs chemotherapy.

What combination therapies lead to more durable responses?

Learn more on this topic: Immunotherapy: Treatment-Related Issues

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on current data on effective immunotherapies.

What are the differences between early and late adverse effects of immunotherapy treatments?

Learn more on this topic: Immune-Related Adverse Events

Brianna Hoffner, MSN, ANP-BC, AOCNP, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on adverse effects of immunotherapy.

How do we understand response patterns in immunotherapy?

Learn more on this topic: Immunotherapy: Treatment-Related Issues

Brianna Hoffner, MSN, ANP-BC, AOCNP, on assessing response in immunotherapy.

How do the side effects of immunotherapy and chemotherapy agents differ?

Learn more on this topic: Immune-Related Adverse Events

Brianna Hoffner, MSN, ANP-BC, AOCNP, on immunotherapy and chemotherapy side effects.